RayKnowChina Research Map
Shortlist

HarbinHarbin Medical University

Second Affiliated Hospital of Harbin Medical University

哈尔滨医科大学附属第二医院

Listed for 23 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Second Affiliated Hospital of Harbin Medical University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Hepatocellular carcinoma肝细胞癌49 papers led
  2. Stomach cancer胃癌35 papers led
  3. Lung cancer肺癌59 papers led
  4. Pancreatic cancer胰腺癌11 papers led
  5. Breast cancer乳腺癌48 papers led
  6. Glioma胶质瘤31 papers led
  7. Osteosarcoma骨肉瘤12 papers led
  8. Gastrointestinal stromal tumour胃肠道间质瘤1 paper led
  9. Neuroblastoma神经母细胞瘤1 paper led
  10. Multiple myeloma多发性骨髓瘤6 papers led
  11. Lymphoma淋巴瘤2 papers led
  12. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病1 paper led
  13. Myasthenia gravis重症肌无力8 papers led
  14. Coronary heart disease冠心病52 papers led2 open trials led
  15. Congenital heart disease先天性心脏病4 papers led
  16. Hepatic echinococcosis肝包虫病0 papers led
  17. Idiopathic pulmonary fibrosis特发性肺纤维化11 papers led
  18. Amyotrophic lateral sclerosis肌萎缩侧索硬化症0 papers led
  19. Fabry disease法布雷病0 papers led
  20. Behçet disease白塞病1 paper led
  21. IgA nephropathyIgA 肾病3 papers led
  22. Congenital diaphragmatic hernia先天性膈疝0 papers led
  23. Familial adenomatous polyposis家族性腺瘤性息肉病1 paper led

Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Hepatoblastoma, Retinoblastoma, Chordoma, Ewing sarcoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, IgG4-related disease, Moyamoya disease, Wilson disease, Biliary atresia, Scoliosis, Anti-NMDA receptor encephalitis, Takayasu arteritis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Pompe disease, Duchenne muscular dystrophy, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 49 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
49
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 6620212022: 6620222023: 141420232024: 151520242025: 882025

4 hospitals in Harbin for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRecurrence & prognosisLocal treatment (ablation, TACE, HAIC)Imaging, AI & early detection
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicineMedical oncologyGastroenterology / hepatology

Over half of these papers are lab or animal studies.

Papers it led49
  1. Clathrin Light Chain B Drives Hepatocellular Carcinoma Progression Through Dual Mechanisms: Small Extracellular Vesicle-Mediated Angiogenesis and the NF-κB-PCLAF Signaling Axis.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  2. Advancements in locoregional therapy for advanced hepatocellular carcinoma: Emerging perspectives on combined treatment strategies.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  3. Exploring extrahepatic metastasis of hepatocellular carcinoma based on methylation driver genes and establishing a prognostic model for hepatocellular carcinoma.2025Gene
  4. SIRT4 is associated with microvascular infiltration, immune cell infiltration, and epithelial mesenchymal transition in hepatocellular carcinoma.2025Histology and histopathology
  5. Disulfidptosis-related genes RPN1 inhibits the progression of hepatocellular carcinoma by regulating cell cycle, may be a new therapeutic targets.2025Inflammation research : official journal of the European Histamine Research Society ... [et al.]Free full text
  6. Celecoxib as a potential treatment for hepatocellular carcinoma in populations exposed to high PFAS levels.2025Journal of hazardous materials
  7. Exploring the mechanism of Naringenin in the treatment of hepatocellular carcinoma based on mRNA sequencing and experimental validation.2025Scientific reportsFree full text
  8. Tumor-resident Malassezia can promote hepatocellular carcinoma development by downregulating bile acid synthesis and modulating tumor microenvironment.2025Scientific reportsFree full text
  9. The resistance to anoikis, mediated by Spp1, and the evasion of immune surveillance facilitate the invasion and metastasis of hepatocellular carcinoma.2024Apoptosis : an international journal on programmed cell deathFree full text
  10. Peripheral T-cell subsets in radiofrequency ablation for tumors from different origins.2024Asian journal of surgery
  11. The Wnt signaling pathway in hepatocellular carcinoma: Regulatory mechanisms and therapeutic prospects.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  12. NHE7 upregulation potentiates the uptake of small extracellular vesicles by enhancing maturation of macropinosomes in hepatocellular carcinoma.2024Cancer communications (London, England)Free full text
  13. Neutrophil extracellular traps promote immune escape in hepatocellular carcinoma by up-regulating CD73 through Notch2.2024Cancer letters
  14. ANGPTL4 Stabilizes Bone Morphogenetic Protein 7 Through Deubiquitination and Promotes HCC Proliferation via the SMAD/MAPK Pathway.2024DNA and cell biology
  15. Angiopoietin-Related Protein 4-Transcript 3 Increases the Proliferation, Invasion, and Migration of Hepatocellular Carcinoma Cells and Inhibits Apoptosis.2024DNA and cell biology
  16. Effect of Deletion of ANGPTL4 Gene on Viability, Migration and Invasion Ability and Apoptosis of Hepatocellular Carcinoma Cells.2024Discovery medicine
  17. Progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma.2024Frontiers in immunologyFree full text
  18. Constructing immune and prognostic features associated with ADCP in hepatocellular carcinoma and pan-cancer based on scRNA-seq and bulk RNA-seq.2024Frontiers in immunologyFree full text
  19. Computed tomography radiomic features and clinical factors predicting the response to first transarterial chemoembolization in intermediate-stage hepatocellular carcinoma.2024Hepatobiliary & pancreatic diseases international : HBPD INT
  20. Construction and validation of prognostic signature for transcription factors regulating T cell exhaustion in hepatocellular carcinoma.2024MedicineFree full text
  21. Tumor-Targeted CO Nanodelivery System Design and Therapy for Hepatocellular Carcinoma.2024Molecular pharmaceutics
  22. GABPA-Mediated Expression of HPN-AS1 Facilitates Cell Apoptosis and Inhibits Cell Proliferation in Hepatocellular Carcinoma by Promoting eIF4A3 Degradation.2024The Turkish journal of gastroenterology : the official journal of Turkish Society of GastroenterologyFree full text
  23. Prognostic factors in patients with first diagnosis of hepatocellular carcinoma presenting with pulmonary metastasis and construction of a clinical prediction model.2024Updates in surgery
  24. Efficacy and Interpretability Analysis of Noninvasive Imaging Based on Computed Tomography in Patients with Hepatocellular Carcinoma After Initial Transarterial Chemoembolization.2023Academic radiology
  25. Contrast-Enhanced CT Imaging Features Combined with Clinical Factors to Predict the Efficacy and Prognosis for Transarterial Chemoembolization of Hepatocellular Carcinoma.2023Academic radiology
  26. Hepatocellular carcinoma immune prognosis score predicts the clinical outcomes of hepatocellular carcinoma patients receiving immune checkpoint inhibitors.2023BMC cancerFree full text
  27. An offline to online cognitive behavioral stress management caring program effectively improves psychological pressure, spiritual well-being, and quality of life in postoperative hepatocellular carcinoma patients.2023Clinics and research in hepatology and gastroenterologyRCT
  28. Deciphering essential druggable genes reveals potential immune-inflammatory axis in hepatocellular carcinoma.2023Computers in biology and medicine
  29. Nanomicelles for GLUT1-targeting hepatocellular carcinoma therapy based on NADPH depletion.2023Drug deliveryFree full text
  30. A radiomics signature associated with underlying gene expression pattern for the prediction of prognosis and treatment response in hepatocellular carcinoma.2023European journal of radiology
  31. The necroptosis related gene LGALS3 can be used as a biomarker for the adverse progression from chronic HBV infection to HCC.2023Frontiers in immunologyFree full text
  32. Clinical-radiomics predictors to identify the suitability of transarterial chemoembolization treatment in intermediate-stage hepatocellular carcinoma: A multicenter study.2023Hepatobiliary & pancreatic diseases international : HBPD INT
  33. Clathrin light chain A facilitates small extracellular vesicle uptake to promote hepatocellular carcinoma progression.2023Hepatology internationalFree full text
  34. Clathrin light chain A-enriched small extracellular vesicles remodel microvascular niche to induce hepatocellular carcinoma metastasis.2023Journal of extracellular vesiclesFree full text
  35. Combining serum AFP and CEUS LI-RADS for better diagnostic performance in Chinese high-risk patients.2023La Radiologia medica
  36. Circ_RBM23 knockdown suppresses chemoresistance, proliferation, migration and invasion of sorafenib-resistant HCC cells through miR-338-3p/RAB1B axis.2023Pathology, research and practice
  37. Comparison of CalliSpheres® microspheres drug-eluting beads and conventional transarterial chemoembolization in hepatocellular carcinoma patients: a randomized controlled trial.2023Radiology and oncologyRCTFree full text
  38. CDCA2 Promotes HCC Cells Development via AKT-mTOR Pathway.2022Analytical cellular pathology (Amsterdam)Free full text
  39. Reprogramming of central carbon metabolism in hepatocellular carcinoma.2022Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  40. Targeting uridine-cytidine kinase 2 induced cell cycle arrest through dual mechanism and could improve the immune response of hepatocellular carcinoma.2022Cellular & molecular biology lettersFree full text
  41. Dual-Energy Computed Tomography Imaging in Early-Stage Hepatocellular Carcinoma: A Preliminary Study.2022Contrast media & molecular imagingFree full text
  42. The Role of ANGPTL Gene Family Members in Hepatocellular Carcinoma.2022Disease markersFree full text
  43. Quantitative dual-energy computed tomography texture analysis predicts the response of primary small hepatocellular carcinoma to radiofrequency ablation.2022Hepatobiliary & pancreatic diseases international : HBPD INT
  44. Exosomes in hepatocellular carcinoma microenvironment and their potential clinical application value.2021Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  45. The clinical value of kinesin superfamily protein 2A in hepatocellular carcinoma.2021Clinics and research in hepatology and gastroenterology
  46. Preparation of Poly[lactic-co-glycolic] Acid Nanospheres and Its Role in Hepatoma Cells.2021Journal of nanoscience and nanotechnology
  47. Integrated Analysis of Angiogenesis-Mediated Tumor Immune Microenvironment Pattern in Hepatocellular Carcinoma (HCC) and a Novel Prognostic Model Construction to Predict Patient Outcome.2021Medical science monitor : international medical journal of experimental and clinical researchFree full text
  48. LncRNA NORAD promotes proliferation, migration and angiogenesis of hepatocellular carcinoma cells through targeting miR-211-5p/FOXD1/VEGF-A axis.2021Microvascular research
  49. Cyclin B1 acts as a tumor microenvironment-related cancer promoter and prognostic biomarker in hepatocellular carcinoma.2021The Journal of international medical researchFree full text

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 35 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.4%.

Papers led
35
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 5520212022: 8820222023: 5520232024: 7720242025: 992025

4 hospitals in Harbin for stomach cancer211 hospitals in China for stomach cancer

No open trial on stomach cancer lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImaging & AIPeritoneal spread & advanced diseaseImmunotherapy & targeted drugs
Departments in papersSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyOphthalmology / neuro-ophthalmology

Over half of these papers are lab or animal studies.

Papers it led35
  1. Ocular Safety Evaluation of Bemarituzumab in FGFR2b-Overexpressing Gastroesophageal Adenocarcinoma: A 42-Week Follow-Up Study.2026Ocular immunology and inflammation
  2. Effect of sodium-reduced potassium-enriched salt substitutes on stomach cancer: the Salt Substitute and Stroke Study (SSaSS).2025BMC medicineRCTFree full text
  3. Investigating the dysregulation of genes associated with glucose and lipid metabolism in gastric cancer and their influence on immunity and prognosis.2025BioFactors (Oxford, England)Free full text
  4. MEF2A, a gene associated with mitochondrial biogenesis, promotes drug resistance in gastric cancer.2025Biochimica et biophysica acta. Molecular basis of disease
  5. Gastric cancer-derived exosomal miR-196a-5p remodels the pre-metastatic niche for peritoneal dissemination.2025Cellular signalling
  6. Magnetic anchors with line-guided endoscopic full-thickness resection for gastric submucosal tumors.2025European journal of medical researchFree full text
  7. Molecular Mechanisms of Neutrophil Extracellular Traps in Promoting Gastric Cancer Epithelial-Mesenchymal Transition Through SERPINE-1 Expression.2025Journal of biochemical and molecular toxicologyFree full text
  8. Artificial Intelligence-Guided Identification of IGFBP7 as a Critical Indicator in Lactic Metabolism Determines Immunotherapy Response in Stomach Adenocarcinoma.2025Journal of cellular and molecular medicineFree full text
  9. Calcium overload via PVT1 reprograms neutrophil fate and constrains gastric cancer progression.2025Journal of translational medicineFree full text
  10. Reprogramming of hsa_circ_0008719 and its target miR-3615 induced by TOB1 in exosomes of gastric cancer cells: a contribution to inhibit gastric cancer progression.2025Scientific reportsFree full text
  11. TOB1 inhibits the gastric cancer progression by focal adhesion pathway and ERK pathway based on transcriptional and metabolic sequencing.2024BMC cancerFree full text
  12. Expression, DNA methylation pattern and transcription factor EPB41L3 in gastric cancer: a study of 262 cases.2024Cell communication and signaling : CCSFree full text
  13. GDF15 enhances anoikis resistance and metastasis of gastric cancer through protective autophagy.2024Cellular signalling
  14. TOB1 modulates neutrophil phenotypes to influence gastric cancer progression and immunotherapy efficacy.2024Frontiers in immunologyFree full text
  15. Application of Computer-Assisted Endoscopic Ultrasonography Based on Texture Features in Differentiating Gastrointestinal Stromal Tumors from Benign Gastric Mesenchymal Tumors.2024The Turkish journal of gastroenterology : the official journal of Turkish Society of GastroenterologyFree full text
  16. MIEN1 on the 17q12 amplicon facilitates the malignant behaviors of gastric cancer via activating IL-6/JAK2/STAT3 pathway.2024The international journal of biochemistry & cell biology
  17. Bromodomain containing 4 inhibition combats gastric precancerous lesions via modulating macrophage polarization.2024Tissue & cell
  18. Neutrophil extracellular traps promote angiogenesis in gastric cancer.2023Cell communication and signaling : CCSFree full text
  19. Effect of NETs/COX-2 pathway on immune microenvironment and metastasis in gastric cancer.2023Frontiers in immunologyFree full text
  20. Identification of lactylation related model to predict prognostic, tumor infiltrating immunocytes and response of immunotherapy in gastric cancer.2023Frontiers in immunologyFree full text
  21. Contribution of PGAP3 co-amplified and co-overexpressed with ERBB2 at 17q12 involved poor prognosis in gastric cancer.2023Journal of cellular and molecular medicineFree full text
  22. Computed tomography-detected extramural venous invasion-related gene signature: a potential negative biomarker of immune checkpoint inhibitor treatment in patients with gastric cancer.2023Journal of translational medicineFree full text
  23. The Overexpression of TOB1 Induces Autophagy in Gastric Cancer Cells by Secreting Exosomes.2022Disease markersFree full text
  24. Fatty acid metabolism is related to the immune microenvironment changes of gastric cancer and RGS2 is a new tumor biomarker.2022Frontiers in immunologyFree full text
  25. Immunoregulation and clinical significance of neutrophils/NETs-ANGPT2 in tumor microenvironment of gastric cancer.2022Frontiers in immunologyFree full text
  26. The promoter methylation drives down-regulation mode of HIC1 in gastric cancer, its molecular characteristics and downstream functional pathways.2022Gene
  27. The Application Value of ceMDCT in the Diagnosis of Gastric Cancer Extramural Vascular Invasion and Its Influencing Factors.2022Journal of healthcare engineeringFree full text
  28. The functional variant in promoter of OVCA1 was associated with the risk of gastric cancer in the northeast Chinese Han population.2022Pathology, research and practice
  29. Involvement of TOB1 on autophagy in gastric cancer AGS cells via decreasing the activation of AKT/mTOR signaling pathway.2022PeerJFree full text
  30. Neutrophil extracellular traps participate in the development of cancer-associated thrombosis in patients with gastric cancer.2022World journal of gastroenterologyFree full text
  31. The rs9953490 polymorphism of DAL-1 gene is associated with gastric cancer risk in the Han population in Northeast China.2021BMC gastroenterologyFree full text
  32. Neutrophil extracellular traps promote gastric cancer metastasis by inducing epithelial‑mesenchymal transition.2021International journal of molecular medicineFree full text
  33. Anxiety and depression in recurrent gastric cancer: Their prevalence and independent risk factors analyses.2021MedicineFree full text
  34. Reminiscence therapy exhibits alleviation of anxiety and improvement of life quality in postoperative gastric cancer patients: A randomized, controlled study.2021MedicineRCTFree full text
  35. ADAMTS12 acts as a tumor microenvironment related cancer promoter in gastric cancer.2021Scientific reportsFree full text

Run the PubMed searchClinicalTrials.gov

Cancer

Lung cancer

肺癌

Led 59 of the 23,356 English-language PubMed papers on lung cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
59
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 101020212022: 131320222023: 111120232024: 101020242025: 15152025

4 hospitals in Harbin for lung cancer251 hospitals in China for lung cancer

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
    Phase
    Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT07010263

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chongqing, Fuzhou, Guangzhou, Harbin, Jiangmen, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xi'an, Xinxiang, Yinchuan, Zhengzhou, Zunyi

  2. Recruiting
    D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
    Phase
    Phase 3
    Started
    2024-03
    Posted
    Registry
    NCT06300177

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 63 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xinxiang, Xuzhou, Zhanjiang, Zhengzhou, Zunyi

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncologyRadiology / nuclear medicineSurgery (general/hepatobiliary/pancreatic)Radiation oncology
Papers it led59
  1. Non-invasive Prediction of Lymph Node Metastasis in NSCLC Using Clinical, Radiomics, and Deep Learning Features From 18F-FDG PET/CT Based on Interpretable Machine Learning.2025Academic radiology
  2. Multimodal Positron Emission Tomography/Computed Tomography Radiomics Combined with a Clinical Model for Preoperative Prediction of Invasive Pulmonary Adenocarcinoma in Ground-Glass Nodules.2025Academic radiology
  3. Development and validation of machine learning models for early diagnosis and prognosis of lung adenocarcinoma using miRNA expression profiles.2025Cancer biomarkers : section A of Disease markersFree full text
  4. Immunoinfiltration Analysis of Mitochondrial Damage-Related Genes in Lung Adenocarcinoma and Construction of a Classification and Prognostic Model Integrated With WGCNA and Machine Learning Algorithms.2025Cancer medicineFree full text
  5. Precise Molecular Subtyping Reveals Heterogeneity of Lung Adenocarcinoma Based on DNA Methylation.2025Current medicinal chemistry
  6. MFAP5 Strengthened the Stem Cell Features of Non-small Cell Lung Cancer Cells by Regulating the FBW/Sox9 Axis.2025Current pharmaceutical biotechnology
  7. Research Trends of Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer: A Bibliometric Analysis.2025Drug design, development and therapyFree full text
  8. Gut microbiota and metabolite features in NSCLC nude mouse models of subcutaneous tumor and leptomeningeal metastasis: a microbiome-metabolome combined analysis.2025Frontiers in cellular and infection microbiologyFree full text
  9. Global research trends of tumor microenvironment in non-small cell lung cancer with epidermal growth factor receptor mutation: a bibliometric analysis from 2014 to 2023.2025Frontiers in immunologyFree full text
  10. From central to peripheral: a novel robotic approach for lobectomy in patients with incomplete pulmonary fissures.2025Journal of robotic surgery
  11. Faster, safer, better recovery: a modified robotic-assisted segmentectomy versus conventional approaches in early stage lung cancer.2025Journal of robotic surgery
  12. Anti-tumor effects and mechanism of the histone demethylase inhibitor GSK-J4 in non-small cell lung cancer cells.2025Medical oncology (Northwood, London, England)Free full text
  13. Lactic acid promotes non-small cell lung cancer progression by down-regulating hexokinase 1 via histone lactylation: A Mendelian randomization study.2025MedicineFree full text
  14. A multilevel genomic approach to uncover causal connections between CPFE and lung cancer subtypes: A two-sample Mendelian randomization study.2025MedicineFree full text
  15. Intrathecal sintilimab for leptomeningeal metastases of non-small cell lung cancer failed from targeted therapy and intrathecal chemotherapy (LMIS study).2025Neuro-oncologyFree full text
  16. Prospective study of dual-phase 99mTc-MIBI SPECT/CT nomogram for differentiating non-small cell lung cancer from benign pulmonary lesions.2024European journal of radiology
  17. Comprehensive analysis of PPP4C's impact on prognosis, immune microenvironment, and immunotherapy response in lung adenocarcinoma using single-cell sequencing and multi-omics.2024Frontiers in immunologyFree full text
  18. SLC12A8 promotes the migration and invasion of non-small cell lung cancer (NSCLC) cells.2024General physiology and biophysics
  19. Combination of arsenic trioxide and apatinib synergistically inhibits small cell lung cancer by down-regulating VEGFR2/mTOR and Akt/c-Myc signaling pathway via GRB10.2024HereditasFree full text
  20. Comprehensive molecular analyses of cuproptosis-related genes with regard to prognosis, immune landscape, and response to immune checkpoint blockers in lung adenocarcinoma.2024Journal of cancer research and clinical oncologyFree full text
  21. Identification of a potential sialylation-related pattern for the prediction of prognosis and immunotherapy response in small cell lung cancer.2024MedicineFree full text
  22. Predicting invasiveness of ground-glass nodules in lung adenocarcinoma: based on preoperative 18 F-fluorodeoxyglucose PET/computed tomography and high-resolution computed tomography.2024Nuclear medicine communicationsFree full text
  23. Identifying crucial lncRNAs and mRNAs in hypoxia-induced A549 lung cancer cells and investigating their underlying mechanisms via high-throughput sequencing.2024PloS oneFree full text
  24. Development and validation of machine learning models for diagnosis and prognosis of lung adenocarcinoma, and immune infiltration analysis.2024Scientific reportsFree full text
  25. Prognostic factors in patients with first diagnosis of hepatocellular carcinoma presenting with pulmonary metastasis and construction of a clinical prediction model.2024Updates in surgery
  26. Identification of immunotherapy biomarkers for improving the clinical outcome of homologous recombination deficiency patients with lung adenocarcinoma.2023AgingFree full text
  27. A novel single-docking direction of the robotic-assisted left upper lobectomy.2023Asian journal of surgery
  28. Effect of AGEs-RAGE system on the efficacy of PD-1 inhibitors in the treatment of driver-gene mutation negative advanced non-squamous non-small cell lung cancer.2023Cellular and molecular biology (Noisy-le-Grand, France)
  29. Development and validation of an artificial intelligence prediction model and a survival risk stratification for lung metastasis in colorectal cancer from highly imbalanced data: A multicenter retrospective study.2023European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  30. m6A-mediated lncRNA NEAT1 plays an oncogenic role in non-small cell lung cancer by upregulating the HMGA1 expression through binding miR-361-3p.2023Genes & genomics
  31. An anoikis-based gene signature for predicting prognosis in malignant pleural mesothelioma and revealing immune infiltration.2023Journal of cancer research and clinical oncologyFree full text
  32. Development and validation of a nomogram for predicting overall survival of resected N2 non-small cell lung cancer patients undergoing neoadjuvant radiotherapy.2023Journal of cancer research and clinical oncologyFree full text
  33. Robot-assisted segmentectomy with improved modified inflation-deflation combined with the intravenous indocyanine green method.2023Journal of robotic surgery
  34. Value of preoperative 18F-FDG PET/CT and HRCT in predicting the differentiation degree of lung adenocarcinoma dominated by solid density.2023PeerJFree full text
  35. Immunogenic cell death-based prognostic model for predicting the response to immunotherapy and common therapy in lung adenocarcinoma.2023Scientific reportsFree full text
  36. LncRNA RP11-58O9.2 predicts poor prognosis and promotes progression of non-small cell lung cancer.2023The Journal of international medical researchFree full text
  37. Comparison of tumor and two types of paratumoral tissues highlighted epigenetic regulation of transcription during field cancerization in non-small cell lung cancer.2022BMC medical genomicsFree full text
  38. The MLR, NLR, PLR and D-dimer are associated with clinical outcome in lung cancer patients treated with surgery.2022BMC pulmonary medicineFree full text
  39. Comprehensive Analysis of Immune Cell Infiltration of m6a-Related lncRNA in Lung Squamous Cell Carcinoma and Construction of Relevant Prognostic Models.2022BioMed research internationalFree full text
  40. Characteristics of Fatty Acid Metabolism in Lung Adenocarcinoma to Guide Clinical Treatment.2022Frontiers in immunologyFree full text
  41. Ultrasound-Targeted Microbubble Destruction: Modulation in the Tumor Microenvironment and Application in Tumor Immunotherapy.2022Frontiers in immunologyFree full text
  42. TRIM44 promotes BRCA1 functions in HR repair to induce Cisplatin Chemoresistance in Lung Adenocarcinoma by Deubiquitinating FLNA.2022International journal of biological sciencesFree full text
  43. Reminiscence therapy involved care programs as an option to improve psychological disorders and patient satisfaction in elderly lung cancer patients: A randomized, controlled study.2022Journal of cancer research and therapeuticsRCT
  44. Response to Letter to the Editor Titled "Focusing on Intrathecal Pemetrexed for Treating Leptomeningeal Metastases from NSCLC?".2022Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  45. LncRNA MATN1-AS1 for Prediction of Prognosis in Osteosarcoma Patients and Its Cellular Function.2022Molecular biotechnology
  46. AIF-1, a potential biomarker of aggressive tumor behavior in patients with non-small cell lung cancer.2022PloS oneFree full text
  47. Robot-assisted thoracic surgery for lung cancer patients with incomplete fissure.2022Surgical endoscopy
  48. A Method to Identify Intersegmental Planes for Robotic-assisted Anatomic Segmentectomy Without Waiting.2022Surgical laparoscopy, endoscopy & percutaneous techniques
  49. Serum tumor necrosis factor-α, interleukin-1β, interleukin-6, and interleukin-17 relate to anxiety and depression risks to some extent in non-small cell lung cancer survivor.2022The clinical respiratory journalFree full text
  50. A novel protein ubiquitination-related five-gene signature predicts overall survival in patients with lung adenocarcinoma.2021AgingFree full text
  51. Potential role of glucosamine-phosphate N-acetyltransferase 1 in the development of lung adenocarcinoma.2021AgingFree full text
  52. Single-cell RNA Sequencing Analysis Identifies Key Genes in Brain Metastasis from Lung Adenocarcinoma.2021Current gene therapy
  53. CLEC12B suppresses lung cancer progression by inducing SHP-1 expression and inactivating the PI3K/AKT signaling pathway.2021Experimental cell research
  54. Response to Letter to the Editor Titled "Intrathecal Pemetrexed: Another Potential Treatment Modality for TKI-Failed Leptomeningeal Metastases?".2021Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  55. Efficacy and Safety of Intrathecal Pemetrexed Combined With Dexamethasone for Treating Tyrosine Kinase Inhibitor-Failed Leptomeningeal Metastases From EGFR-Mutant NSCLC-a Prospective, Open-Label, Single-Arm Phase 1/2 Clinical Trial (Unique 2021Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  56. Prognostic significance of volume-based 18F-FDG PET/CT parameters and correlation with PD-L1 expression in patients with surgically resected lung adenocarcinoma.2021MedicineFree full text
  57. Hospital anxiety and depression scale exhibits good consistency but shorter assessment time than Zung self-rating anxiety/depression scale for evaluating anxiety/depression in non-small cell lung cancer.2021MedicineFree full text
  58. Mechanism of tumor‑derived extracellular vesicles in regulating renal cell carcinoma progression by the delivery of MALAT1.2021Oncology reportsFree full text
  59. Reminiscence therapy-based care program relieves anxiety, depression, and improves quality of life in post-operational non-small cell lung cancer patients.2021The clinical respiratory journalRCT
Chinese-language papers (not in the count)2
  1. [Investigation of Methods and Influencing Factors to Increase the Positive Rate of 
Cytological Pathology of Cerebrospinal Fluid from Lung Cancer Leptomeningeal Metastases].2022Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  2. [Advances in Diagnosis and Treatment of Leptomeningeal Metastasis of Lung Cancer].2022Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
All its trials on ClinicalTrials.gov, any status5
  1. A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation TherapyRecruitingNCT07010263Study sitePhase 3Start 2025-06
  2. D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy FailureRecruitingNCT06300177Study sitePhase 3Start 2024-03
  3. A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerActive, not recruitingNCT06711900Study sitePhase 3Start 2024-10
  4. A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT06448312Study sitePhase 3Start 2024-06
  5. Cancer Genome Atlas of China:Lung CancerStatus unknownNCT04266483Study siteStart 2019-11

Run the PubMed searchClinicalTrials.gov

Cancer

Pancreatic cancer

胰腺癌

Led 11 of the 5,743 English-language PubMed papers on pancreatic cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
11
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 3320222023: 3320232024: 3320242025: 222025

3 hospitals in Harbin for pancreatic cancer192 hospitals in China for pancreatic cancer

No open trial on pancreatic cancer lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)ENT / head & neck surgeryRadiation oncology
Papers it led11
  1. Exosomal Non-Coding RNAs in Pancreatic Cancer: From Mechanisms to Clinical Applications.2025Oncology researchFree full text
  2. PSMD14 Transcriptionally Activated by MEF2A Promotes Pancreatic Cancer Development by Upregulating SPON2 Expression.2025The Kaohsiung journal of medical sciencesFree full text
  3. A rare coexistence of solid pseudopapillary pancreatic tumor and papillary thyroid carcinoma arising from the pyramidal lobe: A rare case report.2024Asian journal of surgery
  4. Circular RNAs in pancreatic cancer progression.2024Clinica chimica acta; international journal of clinical chemistry
  5. Ferroptosis: New Strategies and Ideas for the Treatment of Pancreatic Ductal Adenocarcinoma.2024Frontiers in bioscience (Landmark edition)
  6. Exosomal miRNAs in the microenvironment of pancreatic cancer.2023Clinica chimica acta; international journal of clinical chemistry
  7. Tertiary lymphoid structures in pancreatic cancer: a new target for immunotherapy.2023Frontiers in immunologyFree full text
  8. Extracellular vesicle-derived LINC00511 promotes glycolysis and mitochondrial oxidative phosphorylation of pancreatic cancer through macrophage polarization by microRNA-193a-3p-dependent regulation of plasminogen activator urokinase.2023Immunopharmacology and immunotoxicology
  9. Transcriptional ITPR3 as potential targets and biomarkers for human pancreatic cancer.2022AgingFree full text
  10. Tumor mutation burden-related long non-coding RNAs is predictor for prognosis and immune response in pancreatic cancer.2022BMC gastroenterologyFree full text
  11. An integrated model of acinar to ductal metaplasia-related N7-methyladenosine regulators predicts prognosis and immunotherapy in pancreatic carcinoma based on digital spatial profiling.2022Frontiers in immunologyFree full text
All its trials on ClinicalTrials.gov, any status1
  1. Laparoscopic vs Open Pancreatectomy for Body and Tail Pancreatic CancerStatus unknownNCT03792932Study siteN/AStart 2019-02

Run the PubMed searchClinicalTrials.gov

Cancer

Breast cancer

乳腺癌

Led 48 of the 16,974 English-language PubMed papers on breast cancer with an author in mainland China, 2021–2025: 0.3%.

Papers led
48
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 7720212022: 5520222023: 7720232024: 141420242025: 15152025

4 hospitals in Harbin for breast cancer219 hospitals in China for breast cancer

No open trial on breast cancer lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicineSurgery (general/hepatobiliary/pancreatic)Pathology / laboratory medicineMedical oncology
Papers it led48
  1. Developing and Evaluating a Nomogram Model Predicting Axillary Lymph Node Metastasis of Triple-Negative Breast Cancer Based on Multimodal Imaging Characteristics.2025Academic radiology
  2. N4-Acetylcytidine-Mediated CD2BP2-DT Drives YBX1 Phase Separation to Stabilize CDK1 and Promote Breast Cancer Progression.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  3. Differentiating triple-negative breast cancer and atypical fibroadenomas using an ultrasound-based radiomics nomogram.2025BMC medical imagingFree full text
  4. Prediction model for assessing HER2 status patient with invasive ductal carcinoma based on clinical parameters and ultrasound features: a dual-center study.2025BMC women's healthFree full text
  5. Survival outcomes of neoadjuvant versus adjuvant therapy in patients with T1c, node-negative, human epidermal growth factor receptor 2-positive breast cancer: A Surveillance, Epidemiology, and End Results population-based study.2025Cancer
  6. Prediction of HER2-Low Breast Cancer via Multimodal Ultrasound Imaging.2025Cancer medicineFree full text
  7. Lnc-TPT1-AS1/CBP/ATIC Axis Mediated Purine Metabolism Activation Promotes Breast Cancer Progression.2025Cancer scienceFree full text
  8. FTO promotes the progression of triple-negative breast cancer by regulating the m6A methylation of NFKBIE.2025Clinical and experimental medicineFree full text
  9. Deep Learning for Distinguishing Mucinous Breast Carcinoma From Fibroadenoma on Ultrasound.2025Clinical breast cancer
  10. Tetrandrine and adriamycin reverse multidrug resistance by regulating NLRP3/Caspase-1/GSDMD signaling in human breast cancer cells.2025European journal of pharmacology
  11. Application of Contrast-Enhanced Ultrasound Parameters of Metastatic Axillary Lymph Nodes in Breast Cancer Patients in Predicting the Efficacy of Neoadjuvant Chemotherapy in Early Stage.2025Journal of clinical ultrasound : JCU
  12. Association between albumin-related inflammatory biomarkers and breast cancer risk: A secondary analysis of NHANES 1998-2018.2025MedicineFree full text
  13. Correlation Between the Prognostic Nutritional Index and Breast Cancer in U.S. Adults: NHANES 2001-2018.2025Nutrition and cancer
  14. Identification of a super enhancer associated gene signature for the prognosis prediction and regulatory mechanism exploration in breast cancer.2025Scientific reportsFree full text
  15. Development of a Nomogram-Integrated Model Incorporating Intra-tumoral and Peri-tumoral Ultrasound Radiomics Alongside Clinical Parameters for the Prediction of Histological Grading in Invasive Breast Cancer.2025Ultrasound in medicine & biology
  16. A Mammography-Based Radiomic Nomogram for Predicting Malignancy in Breast Suspicious Microcalcifications.2024Academic radiologyRCT
  17. Radiomic Nomogram for Predicting Axillary Lymph Node Metastasis in Patients with Breast Cancer.2024Academic radiology
  18. Breast cancer clinical outcomes and tumor immune microenvironment: cross-dialogue of multiple epigenetic modification profiles.2024Aging
  19. Preoperative platelet distribution width predicts bone metastasis in patients with breast cancer.2024BMC cancerFree full text
  20. Circular RNAs in Breast Cancer: An Update.2024BiomoleculesFree full text
  21. Comparing survival outcomes between neoadjuvant and adjuvant chemotherapy within T2N1M0 stage hormone receptor-positive, HER2-negative breast cancer: a retrospective cohort study based on SEER database.2024Breast cancer (Tokyo, Japan)Free full text
  22. Neoadjuvant nivolumab plus bevacizumab therapy improves the prognosis of triple-negative breast cancer in humanized mouse models.2024Breast cancer (Tokyo, Japan)
  23. Overexpressing S100A9 ameliorates NK cell dysfunction in estrogen receptor-positive breast cancer.2024Cancer immunology, immunotherapy : CIIFree full text
  24. Associated factors leading to misdiagnosis of a combined diagnostic model of different types of strain imaging and conventional ultrasound in evaluation of breast lesions: Selection strategy for using different types of strain imaging in ev2024European journal of radiology
  25. CHST4 associates with high-abundance immune infiltration in hormone receptor-positive breast cancer.2024Journal of leukocyte biology
  26. Ultrasound-based radiomics nomogram for predicting axillary lymph node metastasis in early-stage breast cancer.2024La Radiologia medica
  27. Clinical Radiologic Analysis of 2964 Papillary Breast Lesions.2024The breast journalFree full text
  28. Inhibition of Lymphangiogenesis: A Protective Role of microRNA 146a-5p in Breast Cancer.2024The breast journalFree full text
  29. A Model Combining Conventional Ultrasound Characteristics, Strain Elastography and Clinicopathological Features to Predict Ki-67 Expression in Small Breast Cancer.2024Ultrasonic imaging
  30. Comparison of breast-conserving surgery without radiotherapy and mastectomy in the treatment of elderly patients with early breast cancer: A PSM and SEER database study.2023Cancer medicineFree full text
  31. Inhibition of lncRNA PCAT19 promotes breast cancer proliferation.2023Cancer medicineFree full text
  32. Silencing MFHAS1 Induces Pyroptosis via the JNK-activated NF-κB/Caspase1/ GSDMD Signal Axis in Breast Cancer.2023Current pharmaceutical design
  33. Deep learning-based classification of breast lesions using dynamic ultrasound video.2023European journal of radiology
  34. Establishment and validation of an ultrasound-based nomogram with risk stratification for short disease-free survival in breast cancer.2023Journal of clinical ultrasound : JCU
  35. Radiogenomic analysis of prediction HER2 status in breast cancer by linking ultrasound radiomic feature module with biological functions.2023Journal of translational medicineFree full text
  36. The Application of Mixed Reality to Sentinel Lymph Node Biopsy in Breast Cancer.2023World journal of surgeryRCT
  37. Intercellular Communication Reveals Therapeutic Potential of Epithelial-Mesenchymal Transition in Triple-Negative Breast Cancer.2022BiomoleculesFree full text
  38. Different precompression does not reduce the diagnostic value of virtual touch tissue imaging and quantification (VTIQ) in breast lesions, especially for the ratio of the shear wave velocity between lesions and surrounding tissues.2022European journal of radiology
  39. Assessing Whether Morphological Changes in Axillary Lymph Node Have Already Occurred Prior to Metastasis in Breast Cancer Patients by Ultrasound.2022Medicina (Kaunas, Lithuania)Free full text
  40. Nomograms predicting recurrence in patients with triple negative breast cancer based on ultrasound and clinicopathological features.2022The British journal of radiologyFree full text
  41. Survival Outcomes of Breast-Conserving Therapy versus Mastectomy in Early-Stage Breast Cancer, Including Centrally Located Breast Cancer: A SEER-Based Study.2022The breast journalFree full text
  42. Identifying ultrasound features of positive expression of Ki67 and P53 in breast cancer using radiomics.2021Asia-Pacific journal of clinical oncology
  43. Association between VEGF single nucleotide polymorphism and breast cancer in the Northern China Han population.2021Breast cancer research and treatment
  44. YY1-mediated long non-coding RNA Kcnq1ot1 promotes the tumor progression by regulating PTEN via DNMT1 in triple negative breast cancer.2021Cancer gene therapy
  45. IGF-1R Transported to the Cell Nuclei to Regulate the Proliferation of Breast Cancer Cells.2021Cell biochemistry and biophysics
  46. Metal Nanoparticles for Photodynamic Therapy: A Potential Treatment for Breast Cancer.2021Molecules (Basel, Switzerland)Free full text
  47. Diagnostic and prognostic role of NR3C4 in breast cancer through a genomic network understanding.2021Pathology, research and practice
  48. Models for Predicting Sentinel and Non-sentinel Lymph Nodes Based on Pre-operative Ultrasonic Breast Imaging to Optimize Axillary Strategies.2021Ultrasound in medicine & biology
Chinese-language papers (not in the count)1
  1. [The surgical management of axillary lymph node disease in breast cancer patients].2024Zhonghua wai ke za zhi [Chinese journal of surgery]
All its trials on ClinicalTrials.gov, any status4
  1. To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast CancerActive, not recruitingNCT05365178Study sitePhase 3Start 2022-07
  2. Validation of the CPS+EG, Neo-Bioscore and Modified Neo-Bioscore Staging Systems After PST of BC in ChinaCompletedNCT03437837Study siteStart 2017-05
  3. Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast CancerStatus unknownNCT01642771Study sitePhase 3Start 2012-06
  4. Clinical Study of Adjuvant Therapy on Post-menopausal Women With Breast Cancer Under the Guidance of the Results of Preoperative EndocrinotherapyStatus unknownNCT01613560Study sitePhase 2Start 2012-05

Run the PubMed searchClinicalTrials.gov

Cancer

Glioma

胶质瘤

Led 31 of the 7,081 English-language PubMed papers on glioma with an author in mainland China, 2021–2025: 0.4%.

Papers led
31
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 7720212022: 8820222023: 2220232024: 5520242025: 882025

4 hospitals in Harbin for glioma187 hospitals in China for glioma

No open trial on glioma lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgeryMedical oncologySurgery (general/hepatobiliary/pancreatic)Pediatrics

Over half of these papers are lab or animal studies.

Papers it led31
  1. A bibliometric analysis of global research trends in autophagy and glioblastomas.2026Naunyn-Schmiedeberg's archives of pharmacology
  2. Immunotherapeutic strategies targeting the PVR-TIGIT/CD96/CD226 signaling pathway in glioma treatment.2025Annals of medicineFree full text
  3. MicroRNA strand ratio disarray promotes temozolomide resistance in glioblastoma.2025Cellular & molecular biology lettersFree full text
  4. Analysis of the Mechanism Underlying Radiotherapy Resistance Caused by Oligodendroglia Cells in Glioblastoma by Applying the Single-cell RNA Sequencing Technology.2025Current medicinal chemistry
  5. Deciphering the carcinogenic role of benzo[a]pyrene in glioblastoma: Insights from network toxicology, single-cell transcriptomics, and Mendelian randomization.2025Ecotoxicology and environmental safety
  6. Ruxolitinib suppresses tumor growth in PTEN-deficient glioblastoma by inhibiting the STAT3-PDL1 axis-mediated the M2 polarization of macrophages.2025International immunopharmacology
  7. Insights of immune cell heterogeneity, tumor-initiated subtype transformation, drug resistance, treatment and detecting technologies in glioma microenvironment.2025Journal of advanced researchFree full text
  8. A novel nuclear RNA HSD52 scaffolding NONO/SFPQ complex modulates DNA damage repair to facilitate temozolomide resistance.2025Neuro-oncologyFree full text
  9. Integrating deep learning and radiomics for preoperative glioma grading using multi-center MRI data.2025Scientific reportsFree full text
  10. LncRNA-Mediated TPI1 and PKM2 Promote Self-Renewal and Chemoresistance in GBM.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  11. EMP3 as a prognostic biomarker correlates with EMT in GBM.2024BMC cancerFree full text
  12. Unveiling the role of TAGLN2 in glioblastoma: From proneural-mesenchymal transition to Temozolomide resistance.2024Cancer letters
  13. Identifying and validating necroptosis-associated features to predict clinical outcome and immunotherapy response in patients with glioblastoma.2024Environmental toxicology
  14. Polymer-locking fusogenic liposomes for glioblastoma-targeted siRNA delivery and CRISPR-Cas gene editing.2024Nature nanotechnology
  15. Histone lactylation-derived LINC01127 promotes the self-renewal of glioblastoma stem cells via the cis-regulating the MAP4K4 to activate JNK pathway.2023Cancer letters
  16. Photodynamic therapy enhances the cytotoxicity of temozolomide against glioblastoma via reprogramming anaerobic glycolysis.2023Photodiagnosis and photodynamic therapy
  17. Dissecting and analyzing the Subclonal Mutations Associated with Poor Prognosis in Diffuse Glioma.2022BioMed research internationalFree full text
  18. Oncogenic Forkhead box D3 antisense RNA 1 promotes cell survival and confers temozolomide resistance in glioblastoma cells through the miR-128-3p/WEE1 G2 checkpoint kinase axis.2022BioengineeredFree full text
  19. Neutrophils: New Critical Regulators of Glioma.2022Frontiers in immunologyFree full text
  20. 5-Methylcytosine Related LncRNAs Reveal Immune Characteristics, Predict Prognosis and Oncology Treatment Outcome in Lower-Grade Gliomas.2022Frontiers in immunologyFree full text
  21. High expression of N-type calcium channel indicates a favorable prognosis in gliomas.2022MedicineFree full text
  22. Identification of COL1A1 associated with immune infiltration in brain lower grade glioma.2022PloS oneFree full text
  23. FBXO31 suppresses lipogenesis and tumor progression in glioma by promoting ubiquitination and degradation of CD147.2022Prostaglandins & other lipid mediators
  24. Simvastatin Inhibits Tumor Growth and Migration by Mediating Caspase-1-Dependent Pyroptosis in Glioblastoma Multiforme.2022World neurosurgery
  25. m6A regulator-mediated methylation modification patterns and characteristics of immunity and stemness in low-grade glioma.2021Briefings in bioinformatics
  26. Glioblastoma Cell-Derived lncRNA-Containing Exosomes Induce Microglia to Produce Complement C5, Promoting Chemotherapy Resistance.2021Cancer immunology research
  27. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.2021Cancer research and treatmentFree full text
  28. Circular RNA circ_ABCB10 in cancer.2021Clinica chimica acta; international journal of clinical chemistry
  29. Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine Development.2021Frontiers in immunologyFree full text
  30. Construction of Interferon-Gamma-Related Gene Signature to Characterize the Immune-Inflamed Phenotype of Glioblastoma and Predict Prognosis, Efficacy of Immunotherapy and Radiotherapy.2021Frontiers in immunologyFree full text
  31. Dihydroartemisinin prompts amplification of photodynamic therapy-induced reactive oxygen species to exhaust Na/H exchanger 1-mediated glioma cells invasion and migration.2021Journal of photochemistry and photobiology. B, Biology

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 12 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.5%.

Papers led
12
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 4420222023: 2220232024: 1120242025: 222025

6 hospitals in Harbin for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgery

Over half of these papers are lab or animal studies.

Papers it led12
  1. Cognitive-behavioral stress management program alleviates anxiety and depression in parents of adolescent patients with osteosarcoma.2026Psychology, health & medicine
  2. BSA-LDHs-cGAMP In Situ Sensitization of Osteosarcoma: Enhancing Antitumor Efficacy with CD40 Agonist Antibodies.2025ACS biomaterials science & engineeringFree full text
  3. MARCH8/NSUN6/ROS-mediated DNA damage positive feedback loop regulates cisplatin resistance in osteosarcoma.2025Cell death and differentiation
  4. 9-O-monoethyl succinate berberine effectively blocks the PI3K/AKT signaling pathway by targeting Wnt5a protein in inhibiting osteosarcoma growth.2024Phytomedicine : international journal of phytotherapy and phytopharmacology
  5. Anticancer effect of crizotinib on osteosarcoma cells by targeting c-Met signaling pathway.2023Cellular and molecular biology (Noisy-le-Grand, France)
  6. PINK1 regulates apoptosis of osteosarcoma as the target gene of cisplatin.2023Journal of orthopaedic surgery and researchFree full text
  7. Oncogenic lncRNA ZNFX1 antisense RNA 1 promotes osteosarcoma cells proliferation and metastasis by stabilizing serine and arginine‑rich splicing factor 3.2022BioengineeredFree full text
  8. lncRNA DARS-AS1 Promoted Osteosarcoma Progression through Regulating miR-532-3p/CCR7.2022Disease markersFree full text
  9. Comprehensive analysis of a glycolysis and cholesterol synthesis-related genes signature for predicting prognosis and immune landscape in osteosarcoma.2022Frontiers in immunologyFree full text
  10. LncRNA MATN1-AS1 for Prediction of Prognosis in Osteosarcoma Patients and Its Cellular Function.2022Molecular biotechnology
  11. ALKBH5 suppresses tumor progression via an m6A-dependent epigenetic silencing of pre-miR-181b-1/YAP signaling axis in osteosarcoma.2021Cell death & diseaseFree full text
  12. Blue LED causes autophagic cell death in human osteosarcoma by increasing ROS generation and dephosphorylating EGFR.2021Journal of cellular and molecular medicineFree full text
Earlier papers (2016–2020)12
  1. LncRNA-SARCC sensitizes osteosarcoma to cisplatin through the miR-143-mediated glycolysis inhibition by targeting Hexokinase 2.2020Cancer biomarkers : section A of Disease markers
  2. LncRNA-XIST promotes the oxidative stress-induced migration, invasion, and epithelial-to-mesenchymal transition of osteosarcoma cancer cells through miR-153-SNAI1 axis.2020Cell biology international
  3. Calcium-sensing receptor activating ERK1/2 and PI3K-Akt pathways to induce the proliferation of osteosarcoma cells.2020Clinical and experimental pharmacology & physiology
  4. Synergistic anti-tumor effects of arsenic trioxide and blue LED irradiation on human osteosarcoma.2019International journal of biological sciences
  5. The expression of Eps15 homology domain 1 is negatively correlated with disease-free survival and overall survival of osteosarcoma patients.2019Journal of orthopaedic surgery and research
  6. Identification of serum miR-124 as a biomarker for diagnosis and prognosis in osteosarcoma.2018Cancer biomarkers : section A of Disease markers
  7. Dopamine D1 receptors induce apoptosis of osteosarcoma cells via changes of MAPK pathway.2017Clinical and experimental pharmacology & physiology
  8. CpG methylation patterns are associated with gene expression variation in osteosarcoma.2017Molecular medicine reports
  9. Single nucleotide polymorphism of hsa-miR-124a affects risk and prognosis of osteosarcoma.2016Cancer biomarkers : section A of Disease markers
  10. Silencing of NUF2 inhibits proliferation of human osteosarcoma Saos-2 cells.2016European review for medical and pharmacological sciences
  11. Hypoxia-induced resistance to cisplatin-mediated apoptosis in osteosarcoma cells is reversed by gambogic acid independently of HIF-1α.2016Molecular and cellular biochemistry
  12. MicroRNA-145 expression in the plasma of patients with benign and malignant bone tumors and its effects on osteosarcoma cell proliferation and migration.2016Panminerva medica

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 1 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

5 hospitals in Harbin for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology
Papers it led1
  1. Application of Computer-Assisted Endoscopic Ultrasonography Based on Texture Features in Differentiating Gastrointestinal Stromal Tumors from Benign Gastric Mesenchymal Tumors.2024The Turkish journal of gastroenterology : the official journal of Turkish Society of GastroenterologyFree full text
Earlier papers (2016–2020)2
  1. [Progression of diagnosis and treatment in primary malignant small bowel tumor].2017Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  2. Submucosal Tunneling Endoscopic Resection (STER) and Other Novel Applications of Submucosal Tunneling in Humans.2016Gastrointestinal endoscopy clinics of North America

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

7 hospitals in Harbin for neuroblastoma321 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 6 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.4%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 2220232024: 0020242025: 002025

3 hospitals in Harbin for multiple myeloma175 hospitals in China for multiple myeloma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Posted
    Registry
    NCT07569757

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDiagnosis, MRD & riskRelapse & resistanceDrug combinations
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Blood disorders

Lymphoma

淋巴瘤

Led 2 of the 3,830 English-language PubMed papers on lymphoma with an author in mainland China, 2021–2025: 0.05%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

3 hospitals in Harbin for lymphoma199 hospitals in China for lymphoma

No open trial on lymphoma lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led 1 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

1 hospital in Harbin for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
    Phase
    Phase 2/Phase 3
    Started
    2024-07
    Posted
    Registry
    NCT06413654

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiamen, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNeurology
Papers it led1
  1. S100A9 as a potential novel target for neuromyelitis optica spectrum disorder.2025Multiple sclerosis and related disorders
Chinese-language papers (not in the count)1
  1. [Advancements and outstanding questions in neuroimmune diseases over the past decade].2024Zhonghua nei ke za zhi
All its trials on ClinicalTrials.gov, any status1
  1. A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)RecruitingNCT06413654Study sitePhase 2/Phase 3Start 2024-07

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 8 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 1.6%.

Papers led
8
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 4420212022: 1120222023: 0020232024: 2220242025: 002025

1 hospital in Harbin for myasthenia gravis89 hospitals in China for myasthenia gravis

No open trial on myasthenia gravis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesEye-only (ocular) myastheniaStandard immunotherapy
Departments in papersNeurologySurgery (general/hepatobiliary/pancreatic)

Over half of these papers are lab or animal studies.

Run the PubMed searchClinicalTrials.gov

Other diseases

Coronary heart disease

冠心病

Led 52 of the 5,119 English-language PubMed papers on coronary heart disease with an author in mainland China, 2021–2025: 1.0%.

Papers led
52
2021–2025
Trials led
12
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 9920212022: 4420222023: 111120232024: 7720242025: 20202025

3 hospitals in Harbin for coronary heart disease231 hospitals in China for coronary heart disease

Open trials with this hospital 5

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Single-cell Multi-omics Analyses of OCT-diagnosed Plaque Subtypes in Coronary Artery Disease (MOOP-CAD)
    Phase
    Not given
    Started
    2024-07
    Posted
    Registry
    NCT06489119

    Age 18 years to 85 years (registered criteria)

    Led by Second Affiliated Hospital of Harbin Medical University; 1 listed hospital as study siteChangchun, Harbin

  2. Enrolling by invitation
    A Coronary Computed Tomography Angiography-guided Intervention for High Risk Cardiovascular Disease Population in Rural China
    Phase
    N/A
    Started
    2026-04
    Posted
    Registry
    NCT07416344

    Age 40 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Harbin Medical UniversityHarbin

  3. Recruiting
    Single vs. Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Intervention With DCB-only Strategy (KONG-FREEDOM-I)
    Phase
    N/A
    Started
    2026-05
    Posted
    Registry
    NCT07587099

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesBeijing, Haikou, Harbin, Jinan, Liaocheng, Nanchang, Qingdao, Urumqi

  4. Recruiting
    Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction
    Phase
    Phase 4
    Started
    2025-11
    Posted
    Registry
    NCT07110415

    Age 40 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Dalian, Daqing, Guangzhou, Guiyang, Hangzhou, Harbin, Huzhou, Jinan, Lanzhou, Nanjing, Nanning, Ningbo, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Tianjin, Xi'an, Yantai, Yinchuan, Zhangjiakou, Zhuhai

  5. Not yet recruiting
    Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System
    Phase
    N/A
    Started
    2021-09
    Posted
    Registry
    NCT04995159

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 67 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Guiyang, Haikou, Hangzhou, Harbin, Hefei, Huai'an, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shantou, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xi'an, Xuzhou, Yantai, Yinchuan, Zhanjiang, Zhengzhou, Zhongshan, Zhuhai, Zibo

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicineNeurosurgeryPathology / laboratory medicine
Papers it led52
  1. Mechanistic study of the effects of different dietary patterns on coronary plaque vulnerability via the dietary inflammatory index in patients with coronary heart disease: A structural equation modeling approach.2026Nutrition, metabolism, and cardiovascular diseases : NMCD
  2. A nomogram-based prediction model for motoric cognitive risk syndrome in patients with coronary artery disease: a cross-sectional study.2025Aging clinical and experimental researchFree full text
  3. Ambient temperature and coronary plaque rupture risk in STEMI: Insights from OCT analysis.2025Atherosclerosis
  4. Comparative outcomes of invasive versus conservative strategy in stable coronary artery disease patients: a risk-stratification-based hypothesis-generative study.2025BMC medicineFree full text
  5. Associations of Plasma Metabolite Phenylacetylglutamine on Coronary Plaque Characterization in Patients with ST-Segment Elevation Myocardial Infarction.2025Cardiovascular toxicology
  6. Association Between the Uric Acid to High-Density Lipoprotein Cholesterol Ratio and Residual Risk for Coronary Artery Disease.2025Cardiovascular toxicology
  7. Safety and Efficacy of Intravascular Lithotripsy System: A Prospective, Multicenter Clinical Trial (The VIGOUR Study).2025Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
  8. Long-Term Prognostic Implications of Non-Culprit Lesions in Patients Presenting With an Acute Myocardial Infarction: Is It the Angiographic Stenosis Severity or the Underlying High-Risk Morphology?2025Circulation
  9. Impact of Carrying DNMT3A or TET2 Mutations on Plaque Characteristics and Prognosis in Patients With STEMI Based on OCT.2025Circulation. Cardiovascular imaging
  10. Impact of non-culprit lesion TCFA on adverse cardiovascular events in patients with diabetes mellitus who present with acute myocardial infarction.2025European heart journal. Cardiovascular Imaging
  11. Type D personality as a risk factor for 3-year cardiovascular events in patients with coronary artery disease and their spouse: a prospective cohort study.2025European journal of preventive cardiology
  12. Circular RNA hsa_circ_0124644 regulates apoptosis of endothelial cells in coronary artery disease.2025In vitro cellular & developmental biology. Animal
  13. Surgical Repair of Ruptured Giant Coronary Artery Aneurysm and Pulmonary Artery Fistula.2025Interdisciplinary cardiovascular and thoracic surgeryFree full text
  14. Carotid Intraplaque neovascularization correlates with coronary atherosclerotic plaque, vulnerability detected by intracoronary optical coherence tomography.2025International journal of cardiology
  15. Artificial intelligence driven plaque characterization and functional assessment from CCTA using OCT-based automation: A prospective study.2025International journal of cardiology
  16. Glycemic control and coronary plaque characteristics in patients with acute myocardial infarction.2025International journal of cardiology
  17. Quantitative flow ratio-based revascularization on clinical outcomes in multivessel disease STEMI patients with chronic kidney disease.2025Journal of cardiology
  18. Non-invasive imaging innovation: FFR-CT combined with plaque characterization, safeguarding your cardiac health.2025Journal of cardiovascular computed tomography
  19. Angiographic Quantitative Flow Ratio-Guided Treatment of Patients With Physiologically Intermediate Coronary Lesions.2025Journal of the American Heart AssociationRCTFree full text
  20. Association of Circulating Phenylacetylglutamine With Multi-Vessel Coronary Disease Severity and Outcomes in ST-Segment-Elevation Myocardial Infarction.2025Journal of the American Heart AssociationFree full text
  21. Higher oxidative balance score is associated with increased plaque stability in patients with coronary heart disease.2025Nutrition, metabolism, and cardiovascular diseases : NMCD
  22. Plaque Ruptures Are Related to High Plaque Stress and Strain Conditions: Direct Verification by Using In Vivo OCT Rupture Data and FSI Models.2024Arteriosclerosis, thrombosis, and vascular biologyFree full text
  23. Revealing the molecular links between coronary heart disease and cognitive impairment: the role of aging-related genes and therapeutic potential of stellate ganglion block.2024BiogerontologyFree full text
  24. A Bidirectional Mendelian Randomization Study of the Causal Association Between Ischemic Stroke, Coronary Heart Disease, and Hydrocephalus.2024Brain and behaviorFree full text
  25. Large-scale, comprehensive plasma metabolomic analyses reveal potential biomarkers for the diagnosis of early-stage coronary atherosclerosis.2024Clinica chimica acta; international journal of clinical chemistry
  26. Rationale and Design of Dual Antiplatelet Therapy in Patients with Coronary Multi-Vessel Disease (DAPT-MVD): A Multicenter, Randomized, Controlled Trial.2024Clinical cardiologyFree full text
  27. The effect of miR-223-3p on endothelial cells in coronary artery disease.2024In vitro cellular & developmental biology. Animal
  28. CDKN2B-AS1 may act as miR-92a-3p sponge in coronary artery disease.2024Minerva cardiology and angiology
  29. Pancoronary plaque characteristics and clinical outcomes in acute coronary syndrome patients with cancer history.2023Atherosclerosis
  30. Association between the stress hyperglycemia ratio and severity of coronary artery disease under different glucose metabolic states.2023Cardiovascular diabetologyFree full text
  31. Combining metabolomics and OCT to reveal plasma metabolic profiling and biomarkers of plaque erosion and plaque rupture in STEMI patients.2023International journal of cardiology
  32. Clinical Characteristics and Prognosis of MINOCA Caused by Atherosclerotic and Nonatherosclerotic Mechanisms Assessed by OCT.2023JACC. Cardiovascular imaging
  33. Exosome-derived circ_0001785 delays atherogenesis through the ceRNA network mechanism of miR-513a-5p/TGFBR3.2023Journal of nanobiotechnologyFree full text
  34. Identification of High-Risk Coronary Lesions by 3-Vessel Optical Coherence Tomography.2023Journal of the American College of Cardiology
  35. High dietary inflammatory index is associated with decreased plaque stability in patients with coronary heart disease.2023Nutrition research (New York, N.Y.)
  36. Safety and effectiveness of nano composite hydrogel stent implantation in the treatment of coronary cardiovascular disease: A preclinical study.2023Preventive medicine
  37. Relationship between stressful life events and coronary plaque vulnerability among patients with acute coronary syndrome: a moderated mediation model of psychological distress and physiological indices.2023Psychology, health & medicine
  38. Type D Personality as a Risk Factor for Adverse Outcome in Patients With Cardiovascular Disease: An Individual Patient-Data Meta-analysis.2023Psychosomatic medicine
  39. Characteristics of coronary artery ectasia and accompanying plaques: an optical coherence tomography study.2023The international journal of cardiovascular imagingFree full text
  40. Impact of nodular calcification in patients with acute coronary syndrome (ACS) treated with primary percutaneous coronary intervention (PCI).2022BMC cardiovascular disordersFree full text
  41. Predictors of Adverse Prognosis in Patients With Acute Coronary Syndrome Caused by Plaque Erosion With a Nonstent Strategy.2022Journal of the American Heart AssociationFree full text
  42. The Potential Mediating Effects of Inflammation on the Association Between Type D Personality and Coronary Plaque Vulnerability in Patients With Coronary Artery Disease: An Optical Coherence Tomography Study.2022Psychosomatic medicine
  43. Optical Coherence Tomographic Features of Pancoronary Plaques in Patients With Acute Myocardial Infarction Caused by Layered Plaque Rupture Versus Layered Plaque Erosion.2022The American journal of cardiology
  44. WeChat-based education and rehabilitation program in unprotected left main coronary artery disease patients after coronary artery bypass grafting: an effective approach in reducing anxiety, depression, loss to follow-up, and improving quali2021Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicasRCTFree full text
  45. Is the effect of atorvastatin 60 mg on stabilization of lipid-rich plaque equivalent to that of rosuvastatin 10 mg? A serial optical coherence tomography combined with intravascular ultrasound imaging.2021Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
  46. Association of the age shock index with coronary plaque characteristics in ST-segment elevation myocardial infarction: A 3-vessel optical coherence tomography study.2021Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
  47. Optical coherence tomography and tailored treatment of in-stent restenosis.2021EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of CardiologyFree full text
  48. Diagnostic utility of circulating plasma microRNA-101a in severity of coronary heart disease.2021Irish journal of medical science
  49. Longitudinal change and prognostic value of anxiety and depression in coronary heart disease patients.2021Irish journal of medical science
  50. Association between food and nutrients intakes and coronary plaque vulnerability in patients with coronary heart disease: An optical coherence tomography study.2021Nutrition, metabolism, and cardiovascular diseases : NMCD
  51. Relationship between non-culprit lesion plaque characteristics changes and in-stent neoatherosclerosis formation: 1-year follow-up optical coherence tomography study.2021Reviews in cardiovascular medicine
  52. Assessment of Left Ventricular Global Myocardial Work in Patients With Different Degrees of Coronary Artery Stenosis by Pressure-Strain Loops Analysis.2021Ultrasound in medicine & biology
Chinese-language papers (not in the count)2
  1. [Annual advances in coronary heart disease imaging research 2024].2025Zhonghua xin xue guan bing za zhi
  2. [Application and evolution of hybrid OCT-IVUS intravascular imaging technique].2021Zhonghua xin xue guan bing za zhi
All its trials on ClinicalTrials.gov, any status20
  1. A Coronary Computed Tomography Angiography-guided Intervention for High Risk Cardiovascular Disease Population in Rural ChinaEnrolling by invitationNCT07416344Lead (inferred)N/AStart 2026-04
  2. Single-cell Multi-omics Analyses of OCT-diagnosed Plaque Subtypes in Coronary Artery Disease (MOOP-CAD)RecruitingNCT06489119Lead (inferred)Start 2024-07
  3. The AIPLAQUE Study: An Artificial Intelligence-based Prospective Study to Analyze PLAQUE Using CCTAStatus unknownNCT05750082Lead (inferred)Start 2021-04
  4. Safety and Efficacy of Drug-Coated Balloon for De-novo Lesions in Patients With Acute Coronary Syndromes (DCB-ACS)CompletedNCT04937803Lead (inferred)N/AStart 2021-04
  5. Primary FIbrinolysis and Secondary STenting Versus immEdiate Stenting in ST-segment Elevation Myocardial InfarctionStatus unknownNCT04663932Lead (inferred)N/AStart 2020-12
  6. PANOVISION: Feasibility and Safety of Hybrid IVUS-OCT SystemCompletedNCT05596279Lead (inferred)N/AStart 2019-11
  7. Peripheral Vascular Disease and Coronary Artery DiseaseCompletedNCT03971864Lead (inferred)Start 2018-11
  8. Clinical Presentations Before AMI Onset and Coronary AtherosclerosisCompletedNCT03107624Lead (inferred)Start 2016-06
  9. Relationship Between Initial Plaque Characteristics and Stent Surface Coverage PatternsTerminatedNCT01024179Lead (inferred)N/AStart 2009-12
  10. Assessment of Surface Coverage of Two Types of Drug-eluting Stent in Diabetes Mellitus and Non-Diabetes MellitusTerminatedNCT01023919Lead (inferred)N/AStart 2009-11
  11. Comparison of Diabetes Mellitus and Non-diabetes Mellitus Patients for DES Surface COVERage by OCTTerminatedNCT01021930Lead (inferred)N/AStart 2009-11
  12. Evaluation of Statin-induced Lipid-rich Plaque Progression by Optical Coherence Tomography (OCT) Combined With Intravascular Ultrasound (IVUS)CompletedNCT01023607Lead (inferred)Phase 4Start 2009-12
  13. Single vs. Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Intervention With DCB-only Strategy (KONG-FREEDOM-I)RecruitingNCT07587099Study siteN/AStart 2026-05
  14. Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac DysfunctionRecruitingNCT07110415Study sitePhase 4Start 2025-11
  15. Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS SystemNot yet recruitingNCT04995159Study siteN/AStart 2021-09
  16. CorVad Percutaneous Ventricular Assist System StudyStatus unknownNCT06198998Study siteN/AStart 2023-10
  17. Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)CompletedNCT04624854Study sitePhase 4Start 2020-10
  18. PROMUS PREMIER™ China Post-Approval StudyCompletedNCT03273023Study siteStart 2018-01
  19. Prospective, Randomized, Multicenter Trial to Assess PROMUS™ Element™ StentCompletedNCT01285999Study siteN/AStart 2011-01
  20. Efficacy and Safety of the YUKON Drug Eluting Stent in Diffuse Coronary Artery DiseaseStatus unknownNCT01418794Study sitePhase 4Start 2010-10

Run the PubMed searchClinicalTrials.gov

Other diseases

Congenital heart disease

先天性心脏病

Led 4 of the 2,604 English-language PubMed papers on congenital heart disease with an author in mainland China, 2021–2025: 0.1%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 0020222023: 1120232024: 0020242025: 002025

1 hospital in Harbin for congenital heart disease207 hospitals in China for congenital heart disease

No open trial on congenital heart disease lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Hepatic echinococcosis

肝包虫病

Led no English-language PubMed papers on hepatic echinococcosis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Harbin for hepatic echinococcosis44 hospitals in China for hepatic echinococcosis

No open trial on hepatic echinococcosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 11 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 1.1%.

Papers led
11
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 1120232024: 2220242025: 552025

3 hospitals in Harbin for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicineNeurologyNephrology
Papers it led11
  1. SCPEP1+ basal cells are associated with the remodeling of oxidative stress signaling networks in idiopathic pulmonary fibrosis.2025Frontiers in immunologyFree full text
  2. Orderly Regulation of Macrophages and Fibroblasts by Axl in Bleomycin-Induced Pulmonary Fibrosis in Mice.2025Journal of cellular and molecular medicineFree full text
  3. YBX1 regulation of alveolar type II epithelial cells in idiopathic pulmonary fibrosis: mechanistic insights and small-molecule drug screening.2025Journal of translational medicineFree full text
  4. Common biomarkers of idiopathic pulmonary fibrosis and systemic sclerosis based on WGCNA and machine learning.2025Scientific reportsFree full text
  5. Rbms1 promotes pulmonary fibrosis by stabilising Sumo2 mRNA to facilitate Smad4-SUMOylation and fibroblast activation.2025The European respiratory journal
  6. Quantitative CT analysis of idiopathic pulmonary fibrosis and correlation with lung function study.2024BMC pulmonary medicineFree full text
  7. Identification of cuproptosis-related diagnostic biomarkers in idiopathic pulmonary fibrosis.2024MedicineFree full text
  8. Bioinformatics approach to identify the hub gene associated with COVID-19 and idiopathic pulmonary fibrosis.2023IET systems biologyFree full text
  9. An 8-ferroptosis-related genes signature from Bronchoalveolar Lavage Fluid for prognosis in patients with idiopathic pulmonary fibrosis.2022BMC pulmonary medicineFree full text
  10. S100A12 as Biomarker of Disease Severity and Prognosis in Patients With Idiopathic Pulmonary Fibrosis.2022Frontiers in immunologyFree full text
  11. CD247, a Potential T Cell-Derived Disease Severity and Prognostic Biomarker in Patients With Idiopathic Pulmonary Fibrosis.2021Frontiers in immunologyFree full text
Earlier papers (2016–2020)1
  1. YAP1/Twist promotes fibroblast activation and lung fibrosis that conferred by miR-15a loss in IPF.2019Cell death and differentiation

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led no English-language PubMed papers on amyotrophic lateral sclerosis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Harbin for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led no English-language PubMed papers on Fabry disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

1 hospital in Harbin for Fabry disease80 hospitals in China for Fabry disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
    Phase
    Not given
    Started
    2025-11
    Posted
    Registry
    NCT07187440

    Age 7 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Nanjing, Shantou, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry DiseaseRecruitingNCT07187440Study siteStart 2025-11

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

2 hospitals in Harbin for Behçet disease139 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 3 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.4%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 0020242025: 112025

4 hospitals in Harbin for IgA nephropathy300 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

Congenital diaphragmatic hernia

先天性膈疝

Led no English-language PubMed papers on congenital diaphragmatic hernia in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Harbin for congenital diaphragmatic hernia44 hospitals in China for congenital diaphragmatic hernia

No open trial on congenital diaphragmatic hernia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led 1 of the 59 English-language PubMed papers on familial adenomatous polyposis with an author in mainland China, 2021–2025: 1.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

1 hospital in Harbin for familial adenomatous polyposis74 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

哈尔滨医科大学附属第二医院

Second Affiliated Hospital of Harbin Medical University

哈尔滨

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Second Affiliated Hospital of Harbin Medical University Harbin; second affiliated hospital of Harbin Medical University

Suggest a correctionDownload the data